Marine natural products and related compounds in clinical and advanced preclinical trials.

By D. Newman, G. Cragg. Journal of Natural Products, 2004

726 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Developing a new resource for drug discovery: marine actinomycete bacteria (2006, background): “Thiocoralin is currently in late preclinical development for the treatment of cance”
NATURAL PRODUCTS: A CONTINUING SOURCE OF NOVEL DRUG LEADS (2013, background): “While research has focused on the discovery of potential new anticancer agents [43, 44], the first marine derived product to gain approval as a drug was Ziconotide, a non-narcotic analgesic that is currently marketed as Prialt® [45].”
Drug development from marine natural products (2009, background): “Indeed, pharmacologically active compounds from plants and microbes represent an important pipeline for new investigational drug”
Sustainability and cyanobacteria (blue-green algae): facts and challenges (2011, background): “Cyanobacteria produce a number of bioactive compounds of potential therapeutic use (Skulberg 2000; Newman et al. 2003; Newman and Cragg 2004a, b; Tan 2007; Gademan and Portman 2008; Jones et al. 2009; Tan 2010).”
Natural products as leads to anticancer drugs (2007, background): “This area of research, which is continually expanding and is of enormous current interest, explores new natural products coming from different sources, among which the sea could be quoted as an almost infinite source of resources [12–19], with a view to collecting more potent, more selective and les”